Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later- Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer

NCT00094094 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00094094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00094094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later- Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2005
Completion date
July 31, 2007
Enrollment
32 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, lung neoplasms